B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies

Moritz F Sinner, Katherine A Stepas, Carlee B Moser, Bouwe P Krijthe, Thor Aspelund, Nona Sotoodehnia, João D Fontes, A Cecile JW Janssens, Richard A Kronmal, Jared W Magnani, Jacqueline C Witteman, Alanna M Chamberlain, Steven A Lubitz, Renate B Schnabel, Ramachandran S Vasan, Thomas J Wang, Sunil K Agarwal, David D McManus, Oscar H Franco, Xiaoyan Yin, Martin G Larson, Gregory L Burke, Lenore J Launer, Albert Hofman, Daniel Levy, John S Gottdiener, Stefan Kääb, David Couper, Tamara B Harris, Brad C Astor, Christie M Ballantyne, Ron C Hoogeveen, Andrew E Arai, Elsayed Z Soliman, Patrick T Ellinor, Bruno HC Stricker, Vilmundur Gudnason, Susan R Heckbert, Michael J Pencina, Emelia J Benjamin, Alvaro Alonso
2014-10-01
Abstract:Aims B-type natriuretic peptide (BNP) and C-reactive protein (CRP) predict atrial fibrillation (AF) risk. However, their risk stratification abilities in the broad community remain uncertain. We sought to improve risk stratification for AF using biomarker information. Methods and results We ascertained AF incidence in 18 556 Whites and African Americans from the Atherosclerosis Risk in Communities Study (ARIC, n=10 675), Cardiovascular Health Study (CHS, n = 5043), and Framingham Heart Study (FHS, n = 2838), followed for 5 years (prediction horizon). We added BNP (ARIC/CHS: N-terminal pro-B-type natriuretic peptide; FHS: BNP), CRP, or both to a previously reported AF risk score, and assessed model calibration and predictive ability [C-statistic, integrated discrimination improvement (IDI), and net reclassification improvement (NRI)]. We replicated models in two …
What problem does this paper attempt to address?